momelotinib news

All news on momelotinib (also known as CYT387 and Ojjaara): plants, production capacities, investments and involved companies.

28 July 2026

GSK Q2: strong core results, R&D acceleration and 20+ Phase III starts in 2026

Core operating profit +7% and core EPS +9%; sales up, driven by Specialty Medicines and Vaccines; new R&D centre and a 3-year £1.9bn annual savings target to fund late-stage pipeline.

Who will be producing momelotinib in the future?

Find out with chemXplore Alpha

Learn more